BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
August 19, 2025Mergers and Acquisitions, Research and Development BioMed X, Novo Nordisk, Pharmacy, drug development, therapeutic peptides
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of therapeutic peptides – a major …
IQVIA and Veeva agree long-term partnerships to support service delivery
August 19, 2025Mergers and Acquisitions Corporate, IQVIA, Veeva Systems
IQVIA and Veeva Systems have announced the formation of global partnerships covering clinical and commercial services. IQVIA provides advanced analytics, …
Graphene-based biosensor to support new lung cancer screening test
August 18, 2025Business Services, Research and Development Ease Healthcare, Hawkeye Bio, HydroGraph, Oncology, lung cancer
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and Ease Healthcare to support the …
Anocca secures £32m to advance pancreatic cancer trial
August 18, 2025Research and Development Anocca, Oncology, Pancreatic cancer, research funding
Swedish biopharma Anocca has raised approximately £32m (SEK 440m) to support the early-stage clinical development of VIDAR-1, its lead TCR-T …
FDA decision on Neurizon’s ALS therapy delayed until October
August 18, 2025Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis
Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …
FDA approves first new fibromyalgia therapy in over 15 years
August 18, 2025Medical Communications, Research and Development Pain, Tonix Pharmaceutical, US Food and Drug Administration, chronic pain, clinical trial, fibromyalgia
The US Food and Drug Administration (FDA) has approved Tonix Pharmaceutical’s Tonmya (cyclobenzaprine hydrochloric acid) for the treatment of fibromyalgia …
Enzybel Pharma 2 and Deebio partner to address pancrelipase shortages
August 15, 2025Manufacturing and Production, Mergers and Acquisitions Deebio, Enzybel Pharma 2, Gastrointestinal tract, Natix, pancrelipase
Enzybel Pharma 2, part of European distributor Natix, has formed an alliance with Chinese enzyme manufacturer Deebio to help alleviate …
NICE recommends Benralizumab for Rare Form of Vasculitis
August 15, 2025Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …
Novartis candidate for Sjögren’s disease presents positive results
August 15, 2025Research and Development Immunology, Novartis, Sjögren’s disease, US Food and Drug Administration, clinical trial
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 – evaluating ianalumab in adults …
KIFFIK Biomedical expands leadership team with two executive appointments
August 14, 2025Research and Development Chief Investment Officer, Corporate, Diagnostics, KIFFIK Biomedical, chief scientific officer
KIFFIK Biomedical has strengthened its leadership team with the appointments of Rene Veloso as chief investment officer and Reginald Swift …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
August 14, 2025Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …
PhotoPharmics expands Parkinson’s Trial into further US states
August 14, 2025Research and Development Neurology, PhotoPharmics, clinical trial, neurodegenerative disorders
US-based PhotoPharmics, has expanded enrollment in its Light for PD clinical trial beyond its original 300 participants, opening new sites …
Medidata appoints Lisa Moneymaker as chief strategy officer
August 13, 2025Clinical Trial Services, Research and Development Corporate, Medidata, chief strategy officer
Medidata has appointed Lisa Moneymaker as chief strategy officer to support the company’s long-term growth in the life sciences technology …
Sandoz signs renewable energy deal to supply 90% of European operations
August 13, 2025Mergers and Acquisitions Corporate, Elawan Energy, Sandoz, decarbonisation, renewable energy
Sandoz has entered into a ten-year virtual Power Purchase Agreement with Elawan Energy for the development of new solar projects …
CuraCell granted approval for trial of new therapy for metastatic cancers
August 13, 2025Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer
Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …
Eyestem secures $10m to advance cell therapy for advanced eye disease
August 13, 2025Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy
Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …
Atelerix appoints new chair and non-executive director to drive global expansion
August 13, 2025Biotech/start-up, Sales and Marketing Atelerix, Corporate, non-executive director
UK-based biotech company, Atelerix, has appointed Sunil Shah as chair of the board and Catherine Elton as non-executive director as …
Sartorius Stedim Biotech partners with Nanotein Technologies to develop cell therapy manufacturing
August 12, 2025Mergers and Acquisitions Corporate, Nanotein Technologies, Sartorius Stedim Biotech, cell therapy, gene therapy
Sartorius Stedim Biotech has partnered with Nanotein Technologies to expand access to immune cell activation reagents for cell therapy manufacturing. …
Enzymatica appoints Sana Alajmovic as new CEO
August 12, 2025Research and Development Corporate, Enzymatica, Infections and infestations
The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step …
OS Therapies advances regulatory pathway for bone cancer therapy
August 11, 2025Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma
OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …
